Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | GGH | Q92820 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26044832 | 1.00 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL12249240 | 0.83 | KISS1R (0.32) | FOLH1ANPEPENPEP | |
| SCHEMBL27437901 | 0.82 | NOD1 (0.33) | NOD1 | |
| SCHEMBL18882590 | 0.82 | FOLH1 (0.40) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL20668143 | 0.82 | FOLH1 (0.40) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL162037 | 0.80 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL180085 | 0.80 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL162038 | 0.80 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL31599178 | 0.80 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL24313096 | 0.80 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLAGGHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094747-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023217744-A1 | PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-11-16 | — | — | WO | disclosed |
| WO-2021186166-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| US-20140018290-A1 | LEPTIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-01-16 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018290-A1 | LEPTIN DERIVATIVES | FABP4, ADIPOR1, ADIPOR2 | FOLH1 595/4885NAALAD2 664/4885RIMKLA 1620/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | FOLH1 81/4885NAALAD2 94/4885RIMKLA 226/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | FOLH1 81/4885NAALAD2 94/4885RIMKLA 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.